Rectify Pharma presented promising preclinical data for RTY-694, their lead candidate for treating primary sclerosing cholangitis and other hepatobiliary diseases, at the 75th Annual Liver Meeting® 2024 in San Diego, California.  In mouse models, RTY-694 improved bile duct health, inflammation, and fibrosis and is now advancing to first-in-human clinical trials for PSC.

Paula Hanford, Chief Executive of PSC Support, remarked: “It is encouraging to see promising data results from PSC research and continued efforts to find effective treatments for this rare disease.”

Learn more about this groundbreaking research here.